Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Docarpamine - Martin Pharmaceuticals

Next Previous
Drug Profile

Docarpamine - Martin Pharmaceuticals

Alternative Names: CIQUAAX

Latest Information Update: 09 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Martin Pharmaceuticals
  • Class Cardiotonics; Catecholamines; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ascites
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ascites

Most Recent Events

  • 03 Dec 2024 Martin Pharmaceuticals entered into a license agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for docarpamine
  • 27 Nov 2024 Efficacy and adverse events data from phase-II DREAM trial in Ascites released by Martin Pharmaceuticals
  • 15 Nov 2024 Efficacy and adverse event data from the phase II DREAM trial in Ascites presented at the 75th Annual Meeting of the American Association for the Study of Liver Diseases 2024 (AASLD-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top